Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial

Benzer Materyaller

• Busulfan 12 mg/kg plus melphalan 140 mg/m2 versus melphalan 200 mg/m2 as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study
  Yazar:: Juan José Lahuerta, ve diğerleri
  Baskı/Yayın Bilgisi: (2010-11-01)
• Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial
  Yazar:: María-Victoria Mateos, ve diğerleri
  Baskı/Yayın Bilgisi: (2015-08-01)
• High‐risk features of early relapse in newly‐diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy
  Yazar:: Andrea Manubens, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-04-01)
• Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high risk smoldering multiple myeloma included in the GEM-CESAR trial
  Yazar:: Noemí Puig, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-07-01)
• Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study
  Yazar:: Verónica González-Calle, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-02-01)